Skip to main content
. 2014 Jul 1;9(7):e100947. doi: 10.1371/journal.pone.0100947

Figure 4. GSK3A inhibition abolishes drug resistance of p53-null colon carcinoma cells by affecting the response to DNA damage.

Figure 4

HCT116p53KO cells stably infected with empty (pRS) and GSK3A shRNA-encoding vector (pRSGSK3A) untreated (cnt) or treated for 18 hrs with 200 µM 5FU (5FU) and stained with anti-γH2AX antibody (A) or anti-RPA70 antibody (B) and counterstained with DAPI. HCT116p53KO untreated (cnt), treated for 18 hrs with 200 µM 5FU (5FU) or with 200 µM 5FU+10 µM SB216763 and stained with anti-γH2AX antibody (C) or anti-RPA70 antibody (D) and counterstained with DAPI.